Novel Molecular Markers in Glioblastoma—Benefits of Liquid Biopsy

Glioblastoma is a primary Central Nervous System (CNS) malignancy with poor survival. Treatment options are scarce and despite the extremely heterogeneous nature of the disease, clinicians lack prognostic and predictive markers to characterize patients with different outcomes. Certain immunohistoche...

Descripción completa

Detalles Bibliográficos
Autores principales: Birkó, Zsuzsanna, Nagy, Bálint, Klekner, Álmos, Virga, József
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7589793/
https://www.ncbi.nlm.nih.gov/pubmed/33053907
http://dx.doi.org/10.3390/ijms21207522

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7589793/
https://www.ncbi.nlm.nih.gov/pubmed/33053907
http://dx.doi.org/10.3390/ijms21207522

Ejemplares similares